OMEICOS closes €8.3 Million Series B

March 03, 2017

Share:

Biotechnology | Berlin, Germany | Series B

Biopharma startup OMEICOS Therapeutics develops small molecules for the prevention and treatment of cardiovascular diseases. The funding will be used to support the initiation of a clinical trial for treating atrial fibrillation. The company raised a €6.2 million Series A in 2015.